

# Transforming Care for Cancer Patients

2019 ANNUAL REPORT HIGHLIGHTS

Our 2019 Annual Report showcases highlights of our clinical and research efforts.

To learn more about our full range of programs and services, please visit [northshore.org/kellogg](http://northshore.org/kellogg)



Dr. Bruce Brockstein



Dr. David J. Winchester

At NorthShore University HealthSystem (NorthShore) Kellogg Cancer Center, we are dedicated to improving patient outcomes. We come together in teams of specially trained physicians, nurses and other healthcare professionals using the most advanced technology and sophisticated personalized medicine to provide the best possible care to individual patients.

From the rapidly evolving world of immunotherapy—which we are prioritizing with a comprehensive new program—to our nationally recognized molecular pathology and diagnostics laboratory, to a wide array of clinical trials and sophisticated surgical techniques, our patients have access to the latest and most effective therapies.

We are also committed to providing a full range of supportive services, like our unique tobacco cessation program and newly available cooling caps to reduce hair loss for patients undergoing chemotherapy.

Our patients also benefit from our academic affiliation with the University of Chicago Pritzker School of Medicine. In addition to our shared medical training programs, patients benefit from our shared clinical and research programs and our combined expertise.

NorthShore is certified by the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) as a premier medical provider for practicing the highest standards of quality cancer care. NorthShore is recognized in *U.S. News & World Report's* Best Hospitals Survey as the #3 Hospital in Chicagoland and the state of Illinois.

We are grateful to our philanthropic supporters and honored by the trust of patients who come to us for care. The highlights described in this report reflect our collective commitment to innovation and outstanding care.

#### Bruce Brockstein, MD

Medical Director, NorthShore Kellogg Cancer Center,  
Head, Division of Hematology/Oncology,  
Kellogg-Scanlon Chair of Oncology

#### David J. Winchester, MD

Chairman, NorthShore Cancer Committee,  
Associate Director for Surgical Specialties,  
NorthShore Kellogg Cancer Center Board of Directors,  
David P. Winchester, MD, Chair of Surgical Oncology



## Progress in Lung Cancer Care

### Innovative Research

NorthShore was one of 18 institutions participating in an important multicenter trial for metastatic non-small cell lung cancer patients. The study aims to determine the best sequencing of chemotherapy and immunotherapy for optimal outcomes. One hundred patients took part in the randomized trial led nationally by NorthShore principal investigator oncologist Thomas Hensing, MD, MS, who presented results at the American Society of Clinical Oncology (ASCO) international conference. Patient outcomes are still being monitored, although initial data revealed that a specific subgroup of patients may benefit the most from chemotherapy first, followed by immunotherapy, said Dr. Hensing, who hopes to continue to build on this study with further research.

### Screening Saves Lives

Another large, randomized trial—the Nelson Study—confirmed that appropriately deployed lung cancer screening saves lives. Presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, the Nelson Study showed that annual lung cancer screening with low-dose computed tomography (CT) in high-risk patients reduced lung cancer deaths by 26% in men and up to 61% in women. Kellogg Cancer Center was an early adopter and promoter of CT lung screening for smokers and former smokers at higher risk of developing lung cancer.

According to the American Cancer Society prediction of 160,000 lung cancer deaths in the United States, screening could save up to 65,000 American lives each year. Lung cancer kills more people annually than breast, colon and prostate cancers combined.



Dr. Thomas Hensing

"We know that lung cancer screening can be effective in high-risk individuals, and we're working with our colleagues in primary care and across the system to build an evidence-based screening program to best serve our patients," said Dr. Hensing.

### Increased Survival Rates

One of NorthShore's key strengths in caring for lung cancer patients is our advanced molecular testing. The ability to do this testing on-site with rapid turnaround is critical to developing personalized treatment plans that offer patients the best care options as quickly as possible. Kellogg Cancer Center team has been a leader in using tumor biology to personalize care and will continue to expand these efforts, which have helped improve survival rates and quality of life.

For more information, visit [northshore.org/cancer](http://northshore.org/cancer) or call (847) 570-2112





Shannon Hartman, PharmD

## Tobacco Cessation Efforts

NorthShore now has three certified Tobacco Treatment Specialists, all of whom completed training at the Mayo Clinic and work tirelessly to help patients quit smoking. Amy Call, PA-C, of the Division of Thoracic Surgery, and JoAnn Eriksson, RN, MS, APN, have joined oncology pharmacist Shannon Hartman, PharmD, who initiated the tobacco cessation program at NorthShore close to 10 years ago, to expand the reach of the program.

"Quitting smoking is different for every person, and we can't compare one smoker to the next. We learn about each patient in one-on-one sessions and develop personally tailored programs to help them quit," said Hartman. "Our program is unique and not based on group sessions." Individual behavior plans to break habits and address triggers are combined with nicotine replacement products and other medications.

Research has shown that these efforts can significantly increase quit rates, and there is strong evidence that continued tobacco use after a cancer diagnosis decreases survival, reduces treatment efficacy, increases/prolongs treatment toxicity and increases the risk of recurrence.

The program is open to all Kellogg Cancer Center patients currently using tobacco, and the team will continue to expand its efforts. Patients can be seen through Kellogg Cancer Center at NorthShore Evanston, Glenbrook and Highland Park Hospitals.

## Lifesaving Collaborative Care

Four years ago, Aislinn Bujewski had a small lump removed from her thigh. A healthy, active 46-year-old mother of three, Bujewski assumed it was a cyst and barely gave it a second thought. When pathology results revealed that it was actually metastatic melanoma, Bujewski was in total shock. "It was one of those surreal moments when it felt like time stopped," she said.

A client/friend of Bujewski's connected her to NorthShore oncologist and Kellogg-Scanlon Chair of Oncology Bruce Brockstein, MD, a specialist with expertise in melanoma, who quickly worked to develop a treatment plan. A PET scan revealed the cancer had already spread to her liver and lymph nodes.

"I told Dr. Brockstein, 'Just come up with a game plan.' I'm very stubborn, and I refused to let this win," said Bujewski, who is a professional horse trainer and avid runner.

Dr. Brockstein started her on an advanced immunotherapy treatment—nivolumab infusions she received every other week for 18 months. "The timing of this was kind of a miracle," said Dr. Brockstein. "Even five years ago, before we had this immunotherapy, she would have likely died in four to six months."

"As scared as I was after the initial diagnosis, within five minutes of meeting Dr. Brockstein, I was thinking 'This is going to be OK.' He was going to be in charge of it, and I felt very calm," said Bujewski. "And the whole team at Kellogg Cancer Center was great. As much as I dreaded the process, everyone from the nurses and techs to the receptionists all made it so much easier."

Although the cancer disappeared from the lymph nodes, the large tumor in the liver remained unchanged in size. Following multidisciplinary consultation, her care team decided that in addition to the immunotherapy, Bujewski should have a major liver resection with Stanton and Margaret Rogers Palmer Chair of Surgery Mark S. Talamonti, MD, who removed the entire right lobe of her liver in an advanced, minimally-invasive procedure.

"This was a remarkable case. We told her we were working with evolving technology, and she had the confidence to go forward," recalled Dr. Talamonti. "She was in such great shape, and there was no evidence of cancer on the healthy section of her liver. She met the highly selective criteria for this pioneering approach." Most, but not the entire removed liver tumor was dead tissue from the immunotherapy.




**Dr. Bruce Brockstein and melanoma survivor Aislinn Bujewski at the Miles for Melanoma 5K Run/Walk in Chicago.**

Bujewski has now been cancer-free for close to four years, and her prognosis is very good, according to Dr. Brockstein.

"I've been very lucky. I never stopped working, and I never stopped working out. I was grateful to keep up my running regimen," said Bujewski, who completed her first marathon in 2018 and has two more on the calendar in 2019.

"This kind of treatment obviously changes your life, but it taught me a lot. It made me realize you're as strong as you need to be," she added. "If I hadn't come to NorthShore for treatment, I'm not sure I'd still be here and able to watch my kids grow up."

## Immunotherapy— Total Number of Patients and Doses



# Advancing Immunotherapy

While different combinations of surgery, radiation, hormonal therapy and chemotherapy have been successful in treating various cancers, physician-scientists continue to seek more effective and less toxic treatments for patients.

Immunotherapy now plays a growing role in the fight against cancer, and Kellogg Cancer Center has been at the forefront of this movement.

Immune checkpoint inhibitors are currently the most widely used and successful type of immunotherapy. These drugs “release the brakes” that keep T cells of the immune system from killing cancer cells. Rather than targeting the tumor directly, these drugs enable the patient’s own immune system to spot cancer cells and destroy them. Immune checkpoint inhibitor drugs have led to remarkably significant improvements in cancer outcomes with fewer side effects.

The first use of modern immunotherapy at Kellogg Cancer Center was for metastatic melanoma in 2011. Now as many as 50% of patients with metastatic melanoma, 25% of lung cancer and kidney cancer patients, as well as others, can expect long-term remission or cure with immunotherapy. Before immunotherapy, that number was closer to zero.

The number of cancers where immunotherapy has shown progress is growing

rapidly. Immune checkpoint inhibitors have now been shown to have a clear benefit for 13 different cancers, and that number will continue to grow with ongoing research.

At Kellogg Cancer Center, we have kept pace with national trends in both clinical use and research on these lifesaving drugs. In fiscal year 2018, a total of 300 patients received immunotherapy. In 2019, 475 are projected—and by 2020, more than 500 (or about 30%) of our medically treated cancer patients will receive immunotherapy.

We are now launching a formal, coordinated Immunotherapy Program at Kellogg Cancer Center to take this work to the next level in both clinical care and clinical and translational research. The dedicated program will build on many existing strengths, including exceptional clinical care and laboratory services.

While we participate in numerous clinical trials involving immunotherapy, the new program will expand our research efforts in clinical and translational research, ensuring that patients have access to the latest advancements. Already our Kellogg Cancer Center team has published several papers and 11 abstracts related to immunotherapy clinical and translational research. The new program will also expand existing partnerships with our collaborators at University of Chicago and other distinguished institutions.

## Molecular Diagnostics Drive Personalized Medicine

NorthShore’s Pathology and Laboratory Medicine Department offers an impressive array of services, including our Molecular Diagnostics Laboratory, an early leader in genomic testing and analysis. We continue to provide next-generation sequencing to analyze tumors at a genetic level and can even analyze micro-needle aspiration samples, all with a rapid turnaround. Results from these high-level tests performed on-site with very rapid turnaround times routinely form the basis for selection of optimal personalized therapy for patients with lung cancer, melanoma, colon and other cancers.

Led by Linda Sabatini, PhD, the Molecular Diagnostics Laboratory is launching new next-generation panels for hematologic malignancies, offering these patients the most advanced DNA-based techniques to deliver personalized care. Clonality testing, launched in 2016, helps in the diagnosis of leukemias and lymphomas.

This year, we will expand our current 50-gene panel test to a 400-plus gene panel test that will include tumor mutational burden, information that can help guide immunotherapy treatment. The analysis of tissue from tumor metastases can identify biomarkers of aggressive behavior, and potential therapeutic targets, potential mechanisms of resistance to therapy. The analysis of circulating tumor DNA (shed into the patient’s bloodstream) can also aid in the identification of biomarkers of resistance and/or response to targeted therapies. The expanded capability will provide a broader view of the genetic alterations in a patient’s tumor.

The Molecular Diagnostics Laboratory is an integral component of NorthShore’s pharmacogenomics program. It is expanding efforts to work with cancer patients and alleviate the need for trial and error with medications for pain management and anxiety/depression.



## Immediate Care by Cancer Specialists

Our new dedicated Kellogg Cancer Center Immediate Care helps patients avoid trips to the Emergency Department by providing expert care for those suffering acute and adverse symptoms related to their disease or treatment.

The Immediate Care Center at Glenbrook Hospital is staffed by oncology advanced practice nurses who assess patients with acute health issues, order appropriate diagnostic tests, and in conjunction with the patient’s physician, decide on a personalized treatment plan of care for less cost than a typical emergency visit. Hospitalization is avoided in 90% of these visits. Research shows that 63% of oncology patients who go to the Emergency Department end up hospitalized.

Patients are seen quickly in a safe environment by those with expertise in cancer care, rather than a potentially long wait in the Emergency Department that may add to the risk in the setting of a compromised immune system.

On-site radiology and laboratory services are available, and complimentary valet parking adds to the ease and convenience of these visits.



# Beating the Odds

Doris Murillo was 52 years old and a self-described workaholic who never took a day off when she had a feeling that something was not right and asked her oldest son to take her to the hospital.

"I was so tired, my chest hurt, my back hurt and I couldn't stop coughing," said Murillo. It didn't take long to learn that she had lung cancer. "I smoked, my friends and family smoked, but still it was a shock. I didn't think it would happen that soon," she recalled.

Murillo was referred to Kellogg Cancer Center oncologist Thomas Hensing, MD, who has treated the now 57-year-old mother of four and grandmother of six with advanced immunotherapy, giving her a new lease on life and time to spend with her family.

"He explained everything in a very detailed way, and he didn't sugarcoat anything," said Murillo, who struggled with her initial chemotherapy and relapsed early in the course of

treatment. Dr. Hensing then put Murillo on an immunotherapy medication, which although not as commonly used for small cell lung cancer like hers, has been very successful in her case. "She's in remission now, and it's very gratifying to be able to offer her this treatment," said Dr. Hensing.

Murillo quit smoking after her diagnosis and hopes everyone in her family will follow. She is grateful for the care she received and for the compassionate caregivers, including Advanced Practice Nurse JoAnn Eriksson and all Kellogg Cancer Center nurses who have been part of her care team.

"Sometimes I get out of breath, but generally I feel OK, and I'm very happy that I'm still here. I thank God for every day, and I'm very thankful for Dr. Hensing. He's been an awesome doctor and a really good person," said Murillo. "I refuse to give up. I don't feel like it's my time yet."



**Advanced Practice Nurse JoAnn Eriksson is a key member of Doris Murillo's care team.**

## Leader in Oncoplastics

Katherine Kopkash, MD, FACS, Director of Oncoplastic Breast Surgery at NorthShore, led a novel study looking at ergonomics for breast surgeons, and presented the results at the national meeting of the American Society of Breast Surgeons in May to an enthusiastic audience. The research will also be published in the *Annals of Surgical Oncology*.



**Dr. Katherine Kopkash**

personal trainer to identify exercises to strengthen the muscles most used during surgery. She also developed an operating room protocol that included specific table positions to help ease muscle strain for surgeons. This study was unique in its consideration of the long-term health and work capacity of the surgeon, recognizing that maximizing the surgeon's comfort maximizes the patient's opportunity for optimal outcomes.

A national leader in the growing field, Dr. Kopkash sits on the Oncoplastics Committee for the American Society of Breast Surgeons and taught its quickly sold-out oncoplastics course hosted at NorthShore. She also held an oncoplastics lab for residents who were able to practice oncoplastic techniques on breast surgical simulators called Mastotrainers. This is the only oncoplastic resident training program in the country. The simulation training was featured in a video presentation at a recent American Society of Breast Surgeons meeting.

Breast surgeons like Dr. Kopkash are doing more and more risk-reducing surgeries as awareness around genetic testing and high-risk patients continues to build. Nipple-sparing mastectomies, which are often favored by patients, are long and complicated procedures that can be physically taxing for surgeons, whose bodies are often contorted for hours.

Dr. Kopkash and three of her colleagues wore EMGs (electromyographs) during surgery to analyze muscle use and then participated in questionnaires after completing procedures. As a follow-up study, Dr. Kopkash used the initial data to develop an exercise program, working with a kinesiologist/

## Crucial Clinical Trials

Patients at Kellogg Cancer Center have access to a broad array of clinical trials and potentially lifesaving new treatments. Research is a critical part of our commitment to providing the best possible care for patients today and driving improvements in treatment.

Surgical Oncology Division Head Katharine Yao, MD, is the site principal investigator of the Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Study, a trial that is studying treatment options for low-risk ductal carcinoma in-situ (DCIS). NorthShore is one of 83 national sites participating in the study, which may prove groundbreaking in how DCIS cancer patients are treated.

The randomized trial assigns patients to one of two groups receiving either: (1) breast surgery with the option of radiation and/or endocrine therapy, and (2) active surveillance or close monitoring with the option of endocrine therapy. The study is sponsored by Alliance Foundation Trials.




**For a complete list of active trials, visit:**  
[northshore.org/Kellogg-cancer-center/clinical-trials](http://northshore.org/Kellogg-cancer-center/clinical-trials)

# Kellogg Cancer Center Nurses Advance Supportive Care

Our specialized oncology nurses led the initiative to provide support for patients experiencing hair loss during chemotherapy.

One of many cancer patients' greatest fears is losing their hair. Kellogg Cancer Center now offers patients undergoing specific types of chemotherapy treatments the option of new scalp cooling caps to reduce hair loss. The cooling caps are not appropriate for all patients but offer a good option for those receiving certain chemotherapy drugs and who are very committed to minimizing hair loss.

The Paxman caps are worn for 30 minutes before treatment, through chemotherapy and up to an additional 90 minutes after the treatment. The cap reduces the temperature of the scalp, which reduces the blood flow to hair follicles to prevent or minimize hair loss. Kellogg Cancer Center nurse Bonnie Ryszka, RN, spearheaded the effort to bring the cooling cap program to NorthShore patients.



**Kellogg Cancer Center staff nurses received national recognition** by presenting at the Oncology Nursing Society (ONS) 44th Annual Congress in April on two important topics: "Simulation as a Unique Training Approach for Nursing Management of Oncologic Emergencies" and "Implementing a Cost-Free Dedicated Education Program for Outpatient Oncology Nurses." Laura Lenski, RN, was the main presenter, supported by Mary Ried, RN, and Bonnie Ryszka, RN.

## Community Partners

**Kellogg Cancer Center has a number of key partnerships and collaborations.**

- **Social workers, nutritionists and financial advocates are connected to internal collaborators and external organizations where we can refer patients for additional resources.**
- **Our outreach coordinator fosters key partnerships with the Cancer Wellness Center, Leukemia & Lymphoma Society, the American Cancer Society (ACS) and others.**
- **We host monthly Imerman Angels socials and partner with ACS for virtual programs and more.**

## Fueling the Fight

Registered dietitians with specialized oncology expertise see patients at all three Kellogg Cancer Centers, as nutrition is an important part of the treatment and healing process. *Fueling the Fight: Recipes with Cancer-Fighting Benefits*, an online cookbook with some of our dietitians' favorite recipes, was released this year.

A well-balanced meal with cancer-fighting benefits, including phytochemicals, does not have to be difficult to create or boring to eat. Phytochemicals are protective compounds found in the pigments of plants



**To download the free eBook, go to [northshore.org/fuelingthefight](http://northshore.org/fuelingthefight)**

Cancer Center dietitians focus on prevention as well as helping cancer patients get stronger through treatment, and the online presence is one way to reach as many members of the community as possible.

## Benefit Concert Supports Integrative Medicine

Close to 1,000 people attended a benefit concert for NorthShore's Integrative Medicine Program on a snowy January evening, raising funds to provide integrative medicine therapies including acupuncture, bodywork and integrative medicine physician consultations for Kellogg Cancer Center patients.

Sons of the Silent Age performed David Bowie's "Scary Monsters" and other Bowie hits at the Metro in Chicago. Actor Michael Shannon joined the band as Lou Reed.



**Dr. Leslie Mendoza Temple is the Medical Director of the Integrative Medicine Program, which provides complementary therapies to a growing number of cancer patients.**

Integrative medicine therapies have been shown to relieve pain and neuropathies, reduce fatigue and sleep issues, boost immunity, provide stress relief, improve appetite and improve quality of life for cancer patients undergoing chemotherapy and radiation.

NorthShore's Integrative Medicine Program celebrated its 20th year and continues to care for a significant number of oncology patients.



# Outcomes Study: Mammogram Screenings for the Underserved

Cancer screening activities are vital work for quality cancer programs. They are designed to decrease the number of patients diagnosed with a specific cancer at a late stage and increase the likelihood of survival.

Breast cancer is the second leading cause of cancer-related death among women. Screening mammography is associated with a 30% to 40% reduction in breast cancer mortality among women ages 40 to 74. Early detection through screening is key to improved survival. The overall prognosis is directly linked to the stage of the disease at diagnosis, and timely screening detects breast cancer at earlier stages when the disease is more treatable and even curable.

To address screening needs and access to screening for the underserved, NorthShore partnered with the Lake County Health Department (LCHD) and Community Health Center, located in Waukegan, and offered 200 complimentary mammograms. The screenings were funded by the Myra Rubenstein Weis (MRW) Leadership Board of NorthShore.

Lake County towns—particularly Highwood, North Chicago, Round Lake, Waukegan and Zion—were identified by NorthShore’s Community Health Needs Assessment as geographic areas of greatest need. Also noted was a higher incidence of breast cancer in Lake County (136.5 per 100,000 compared to 127.4 per 100,000 in Illinois and 122.7 per 100,000 in the United States).

Carol Rosenberg, MD, Director of Preventive Health Initiatives at NorthShore, Director of the MRW LIFE Cancer Survivorship Program, and a member of the cancer committee, is studying the results of complimentary screenings offered to those in the community who are cared for by the Lake County North Shore Health Center in Highland Park.

“Importantly—although about half of those screened were found to have a normal mammogram and were advised to receive normal interval follow-up—a significant number of women were also found to have abnormalities, which were scrutinized intensively by our trained radiologists and deemed benign. These patients were also advised to receive normal interval follow-up,” said Dr. Rosenberg.

A small number of patients had diagnostic findings, which were indeterminate or suspicious for malignancy and given appropriate follow-up recommendations (see chart to the right). Additional significance of the data implies that mammography itself is only one aspect of screening underserved populations. “Imaging in conjunction with follow-up comparisons, additional imaging and feedback to patients and their primary care physicians is the type of complete, multistep quality process with lifesaving value that we were able to provide with this project,” she added.

## LCHD Breast Imaging Categories

	Total LCHD Patients
No Show/Canceled Appointment	37
Scheduled/Awaiting Results	0
(0) Incomplete Additional Imaging or Priors Needed <i>(all contacted)</i>	18
(1) Normal (normal interval follow-up)	98
(2) Benign (normal interval follow-up)	45
(3) Probably Benign (short-term follow-up)	4
(4) Suspicious/Recommending Biopsy	1
(5) Highly Suggestive Malignancy	0
<b>TOTAL</b>	<b>166</b>



Lake County Health Department Executive Director Mark Pfister (from left) with NorthShore’s Chief of Breast Imaging Dr. Georgia Spear and Founding Director of the MRW LIFE Cancer Survivorship Program Dr. Carol Rosenberg celebrate the MRW Leadership Board of NorthShore’s support of mammograms for underserved women in Lake County.

# Support Kellogg Cancer Center

For nearly 40 years, Kellogg Cancer Center’s dedicated team of outstanding physicians, nurses and other care providers has actively pursued the most effective and cutting-edge treatments available. These treatments are provided with compassion in an environment that promotes best practices through advanced research, clinical trials, personalized medicine and many years of collective experience. Kellogg Cancer Center has a truly patient-centered approach at its core and a team that delivers on that promise.

Philanthropy established Kellogg Cancer Center and continues to play an integral role in its success. The pace of change and advances in science and technology are ever-present. Having access to critical resources is paramount to a thriving center of medical excellence. When you donate to Kellogg Cancer Center,

you help ensure that everyone receives the best care possible with personalized care plans tailored specifically for the individual. As a result, you help save and improve the lives of thousands of patients annually—family, friends and your neighbors. Your impact is enormous.

More people are beating cancer than ever before thanks to new discoveries, advances in genomics and other diagnostic testing, personalized targeted therapies, and immunotherapy. There are more options delivering better outcomes and brighter futures.

To learn more about how you can support Kellogg Cancer Center, please call (224) 364-7200 or visit [foundation.northshore.org](http://foundation.northshore.org).

# Active Clinical Trials

**NorthShore patients have access to a broad array of clinical trials and potentially lifesaving new treatments.**

**For a complete list of active trials, visit [northshore.org/kellogg-cancer-center/clinical-trials](http://northshore.org/kellogg-cancer-center/clinical-trials).**

## Brain Tumors

**A071101** Phase II randomized trial comparing the efficacy of heat shock protein-peptide complex-96 (HSPPC-96) (NSC #725085, Alliance IND #15380) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma multiforme (GBM)

**A221101** Phase III randomized, double-blind, placebo-controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with glioblastoma multiforme

**Tocagen/Tg 511-15-01** A Phase I/II randomized, open-label study of Toca 511, a retroviral replicating vector, combined with Toca FC versus standard of care in subjects undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma

**ICT 107 STING** (Study of Immunotherapy in Newly Diagnosed Glioblastoma): A Phase III randomized, double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

**A071102** A Phase I/II randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation

**AbbVie/M13-813** A randomized, placebo-controlled Phase IIb/III study of ABT-414 with concurrent chemoradiation and adjuvant temozolomide in subjects with newly diagnosed glioblastoma multiforme (GBM) with epidermal growth factor receptor (EGFR) amplification (Intelligence 1)

**CDX110-05** Expanded access (compassionate use) treatment protocol, rindopepimut (CDX-110)

**AbbVie Preapproval Access** Preapproval access of ABT-414 for treatment of glioblastoma multiforme (GBM)

## Breast Cancer

**EA221405** Pregnancy outcome and safety of interrupting therapy for women with endocrine responsive breast cancer (POSITIVE)

**EA1131** Randomized Phase III postoperative trial of platinum-based chemotherapy versus observation in patients with residual triple-negative basal-like breast cancer following neoadjuvant chemotherapy

**NSABP B-51** A randomized Phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathology negative axillary nodes after neoadjuvant chemotherapy

**A0011401** Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

**A0011502** A randomized Phase III double-blind placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: The ABC trial

**UC16-0403** A randomized, placebo-controlled, double-blind, Phase II trial of nanoparticle albumin-bound paclitaxel (nab-paclitaxel, Abraxane) with or without mifepristone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer

## Gastrointestinal Cancer

**NRG-GI004/SWOG-S1610** Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

**EA2165:** A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

**A021502** A Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

## Genitourinary Cancer

**Janssen 64091742PCR2001** A Phase II Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

**AFT-19** A Phase III Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

**PCCTC c16-168** A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

**EA8163** Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease Following Docetaxel; The CHAARTED 2 Trial.

## Gynecologic Cancer

**GOG0238** Randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus

**NRG-GY005** A randomized Phase II/III study of the combination of cediranib and olaparib compared to cediranib or olaparib alone, or standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube or primary peritoneal cancer

**GOG0264** A randomized Phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed advanced-stage and recurrent chemo-naïve stage sex cord-stromal tumors of the ovary

**UC13-1235** Randomized, placebo-controlled Phase II trial of metformin in conjunction with chemotherapy followed by metformin maintenance therapy in advanced-stage ovarian, fallopian tube and primary peritoneal cancer adjuvant treatment

**Pilot Study** Pilot study of the impact of early palliative care on quality of life in recurrent ovarian, fallopian tube and primary peritoneal cancer

**AGCT1531** A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

**NRG-GY009** A Randomized Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND 134427) Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

**GOG-3026** A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum

## Head and Neck Cancers

**HCN** Tissue bank tissue/body fluid procurement and clinical data collection for patients with malignancies of the head and neck area and/or premalignant changes

**EA3132** Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

**Merck 3475-689** A Phase III Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable, Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

**Enzychem EC-18-202** A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EC-18 in Altering the Severity and Course of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation Therapy for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx.

## Hematology

**UC14-0899** Phase II randomized trial of continuation of post-transplant maintenance with single-agent lenalidomide versus consolidation/maintenance with ixazomib-lenalidomide-dexamethasone in patients with residual myeloma

**Connect MDS AML** The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

**E1910** Phase III randomized trial of blinatumomab for newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia in adults

**CIBMTR** Research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries

**UC13-1406** Prospective, Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

**E1A11** Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

**A061202** A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy

**TG Therapeutics TGR-205** A Phase IIb Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 Alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

**A041501:** A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody to Frontline Therapy in Young Adults (ages 18-39) with Newly Diagnosed Precursor B-Cell ALL.

**UC16-1138** Open-label, Single-arm, Phase 2 Study of Initial Treatment with Elotuzumab, Carfilzomib (Kypriol), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRD) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

**A041702** A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 years of Age) with Chronic Lymphocytic Leukemia (CLL)

**EA9161** A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib to Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

## Lung Cancer

**Merck 3475-789** A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-Resistance EGFR Mutated Patients in Metastatic Non-Squamous, Non-Small Cell Lung Cancer (NSCLC) Participants (KEYNOTE 789)

**LungMAP** A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

**Merck 3475-799** A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)

**S1900A** A Phase II Study of Rucaparib in Patients with Genomically LOH High And/or Deleterious BRCA 1 / 2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-study)

**S1800A** A Phase II Study of Ramucicrumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients with Previously Treated Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

**EA5163/S1709 INSIGNA** A Randomized, Phase III Study of Firstline Immunotherapy Alone or In Combination with Chemotherapy Induction/Maintenance or Post-progression in Advanced, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker Signature-driven Analysis



**NRG LU003** A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol

**Helsinn ANAM 17-21** A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Evaluated the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

## Sarcoma

**A091401** Randomized Phase II study of nivolumab with or without ipilimumab in patients with metastatic or unresectable sarcoma

## Skin Cancer

**EA6141** Randomized Phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

**EA6134** A Randomized Phase III Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression Versus Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

## Other

**EAY131** Molecular Analysis for Therapy Choice (MATCH)

**EAY131-C2** Crizotinib in patients with tumors with MET exon 14 deletion

**EAY131-T** GDC-0449 (vismodegib) in patients with tumors (except basal cell skin carcinoma) with smoothened (SMO) or patched 1 (PTCH1) mutations

**EAY131-E** AZD9291 in patients with tumors having EGFR T790M mutations (except non-small cell lung cancer) or rare activating mutations of EGFR

**EAY131-V** Phase II study of sunitinib in patients with tumors with c-kit mutations (excluding GIST, renal cell carcinoma or pancreatic neuroendocrine tumor)

**EAY131-Z1C** Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification

**EAY131-Z1E** LOXO-101 in Patients with Tumors with NTRK Fusions

**EAY131-Z1F** Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

**EAY131-Z1H** Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC

**EAY131-Z1G** Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

**EAY131-M** Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

**EAY131-L** Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

**EAY131-J** Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification

**EAY131-K1** Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications

**EAY131-K2** Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions

**ACCRU SC-1601** A Phase III, randomized, controlled, double-blind study evaluating the safety of two doses of apixaban for secondary prevention of cancer-related venous thrombosis in subjects who have completed at least six months of anticoagulation therapy

## Breast Surgery

**EH15-297** A randomized Phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy—Alliance A011202

**EH15-308** Using genetic risk scores to assess the efficacy of mammography screening among women diagnosed with breast cancer

**EH16-063** Germline genetic profiles associated with contralateral breast cancer patients

**EH14-020** Piloting an In-Visit Decision Aid for Surgical Decision-Making in Breast Cancer Patients

**EH17-026** A Database of Contralateral Breast Cancer at NorthShore University HealthSystem

**EH17-045** Impact of an In-Visit Decision Aid on Uninformed Decision-Making for Contralateral Prophylactic Mastectomy

**EH16-343** Retrospective Review of HER2/neu Positive Breast Cancer Patients to Examine Loco-Regional Recurrence Rates

**EH18-203** Mindfulness-Enhanced Decision Intervention to Aid Treatment Election—Breast Cancer

**EH17-072** Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS

**EH17-209** Genetic Determinants of Cooperative Interactions on Breast Cancer Intratumor Heterogeneity

**EH18-243** Tell Me Where It Hurts: The Ergonomic Effects of Mastectomies on the Operating Surgeon

## Colorectal Surgery

**EH12-468 N1048** A Phase II/III trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision

**EH16-280** The creation and establishment of a colorectal tumor database and biorepository

## Head and Neck Surgery

**EH19-176** Transoral Robotic Surgery (TORS) Database

**EH17-040** Surveillance Imaging Practice Patterns in Head and Neck Cancer Patients

**EH17-116** Lipid Tissue from Head and Neck Cancer

**EH19-145** KTP Laser Treatment of Early Glottic Cancer: A Multi-Institutional Retrospective Study

**EH19-081** Assessment of Allergies in Patients with Oral Cavity Cancers

**EH18-179** The Patient Decision-Making Process after a Diagnosis of Oral Cavity Cancer

**EH19-021** A Multicenter Trial of a Patient Education Handout for Head and Neck Free Flap Surgery

## Pancreatic Cancer

**EH18-265** A Phase III Multicenter, Open-Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy

**EH08-1977** Clinical pancreatic cancer database

**EH13-433** Comprehensive Assessments for Clinical Care and Surgical Management Among Individuals with Pancreatic Pathology

**EH02-186** The Pancreatic Sample Repository

**EH17-132** Assessment of Tumor and Treatment Factors as Predictors of Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma Undergoing Pancreatoduodenectomy, and Efficacy of Pharmacologic Prophylaxis

## Lung and Esophageal Cancer

**EH98-136** Establishment and maintenance of a comprehensive thoracic tumor data registry and biorepository

**EH15-121 E4512** A Phase III double-blind trial for surgically resected early-stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein

**EH15-122** Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

**EH15-123 A081105** Randomized, double-blind, placebo-controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

**EH16-268 EA5142** Adjuvant nivolumab in resected lung cancers (ANVIL): A randomized Phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers

**EH18-162** Inherited Cancer Panel Performance in Predicting Outcomes Among Patients Diagnosed with Lung Cancer

**EH16-356** Clinical Characteristics of Anti-PD-1/PD-L1 relapses in Non-Small Cell Lung Cancer (NSCLC)

**EH16-079** Retrospective Chart Review Study to look at adequacy of lymph node staging in patients undergoing curative anatomic resection for non-small cell lung cancer

**EH16-362** Natural History of Indeterminate Lung Nodules

## Thyroid Surgery

**EH14-058** The establishment of a multidisciplinary comprehensive database of patients for thyroid nodular disease

**EH18-163** Predictors of Surgery and Malignancy Among Thyroid Nodule Patients

## Genitourinary Cancer

**EH09-043** A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

**EH10-089** Periprostatic fat as a promoter of prostate cancer progression

**EH10-379** Three-dimensional transrectal ultrasound for prostate cancer diagnosis and surveillance

**EH13-049** Compliance and outcomes with penile rehabilitation in men after prostate cancer treatment

**EH13-088** Mind-body health in uro-oncology

**EH13-250** Cancer susceptibility: The ICPG study (International Consortium for Prostate Cancer Genetics)

**EH13-446** A retrospective review of patients who have been removed from study EH09-043: A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

**EH14-133** The Lived Experience of Men with Sexual Dysfunction after Prostate Cancer Treatment

**EH15-240** Urologic oncology: Costs and complications

**EH14-206** Nanocytology to mitigate overdiagnosis of prostate cancer

**EH14-361** SPORE Project 1: Impact of Germline Genetic Variants and Failure of Active Surveillance for Prostate Cancer

**EH16-009** Clinical validation of a urine-based assay with genomic and epigenomic markers for predicting recurrence during non-muscle invasive bladder cancer surveillance

**EH16-183** Evaluation of the utility of the prostate health index in routine clinical practice

**EH16-202** Detecting copy number alterations (CNAs) of MYC and PTEN in biopsy samples to predict clinical outcomes in prostate cancer

**EH16-232** Trends in upper tract urothelial treatment

**EH16-240** Timing of artificial urinary sphincter placement

**EH15-124** Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education (REASSURE ME)

**EH15-403** Mindfulness online for symptom alleviation and improvement in cancer of the prostate (MOSAIC-P)

**EH16-236** Novel genetic markers for predicting clinical outcomes in patients with high-grade superficial bladder cancer

**EH16-239** The impact of using genetic risk scores (GRSs) for inherited risk assessment of prostate cancer

**EH16-237** A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance (ENACT)

**EH16-387** Risk-Stratification of Prostate Cancers via Field Carcinogenesis Nanocytology

# Cancer Data Summary 2018

## Incidence of Cancer 2018

In 2018, 4,258 new cancer cases were accessioned into the NorthShore University HealthSystem (NorthShore) Cancer Registry. Of those 4,059 cases (95%) were analytic. By definition, analytic cases are those patients newly diagnosed with malignant neoplasm and/or who have received all or part of their first course of treatment at one of our hospitals. The remaining 199 cases (5%) were non-analytic. Non-analytic cases are patients initially diagnosed and treated at another facility who now are receiving treatment for progression or recurrence of their disease at NorthShore. Details by site are provided in Table 1.

## Class of Case 2018

Class of Case divides cases into two groups, analytic cases (Class 00-22) and non-analytic cases (Class 30-49).

Class 00-14, which account for 3,486 cases, were those malignancies diagnosed at one of our four hospitals or in an office of our medical group. Once diagnosed with cancer, 3,275 (94%) of our patients remained at NorthShore for their treatment. Class 20-22, totaling 573 cases, were diagnosed elsewhere and referred here for treatment. Class 30-49, a total of 199 cases, were diagnosed and treated elsewhere and referred here for treatment of a recurrence or progression of disease.

## Overall Top 10 Sites 2018

The top 10 cancers seen at NorthShore are breast (830), prostate (472), lung and bronchus (359), skin (304), lymphoma (179), bladder (176), central nervous system (177), colon (167), corpus uteri (164) and thyroid (135). These top 10 sites represent 70% of all cancers seen at NorthShore.

Among women, breast cancer continues to be our top site representing 20% of the total cases seen at NorthShore. The next most frequent cancers seen in women were lung, corpus uteri, skin and central nervous system.

Among men, prostate cancer continues to be our top site representing 11% of the total cases seen at NorthShore. The next most frequent cancers seen in men were skin, lung, bladder and lymphoma.

**Table 1: Incidence of Cancer—2018 Data Summary**

Primary Site	Analytic	Non-Analytic	Total	Percentage
<b>ORAL CAVITY &amp; PHARYNX</b>	<b>86</b>	<b>4</b>	<b>90</b>	<b>2.1</b>
Lip	1	0	1	0.0
Tongue	31	3	34	0.8
Salivary Glands	13	0	13	0.3
Floor of Mouth	3	1	4	0.1
Gum & Other Mouth	13	0	13	0.3
Nasopharynx	1	0	1	0.0
Tonsil	12	0	12	0.3
Oropharynx	6	0	6	0.1
Hypopharynx	5	0	5	0.1
Other Oral Cavity & Pharynx	1	0	1	0.0
<b>DIGESTIVE SYSTEM</b>	<b>559</b>	<b>19</b>	<b>578</b>	<b>13.6</b>
Esophagus	30	1	31	0.7
Stomach	55	5	60	1.4
Small Intestine	15	1	16	0.4
Colon Excluding Rectum	165	2	167	3.9
Rectum & Rectosigmoid	69	2	71	1.7
Anus, Anal Canal & Anorectum	14	3	17	0.4
Liver & Intrahepatic Bile Duct	43	2	45	1.1
Gallbladder	14	0	14	0.3
Other Biliary	20	0	20	0.5
Pancreas	123	3	126	3.0
Retropertitoneum	1	0	1	0.0
Peritoneum, Omentum & Mesentery	4	0	4	0.1
Other Digestive Organs	6	0	6	0.1
<b>RESPIRATORY SYSTEM</b>	<b>379</b>	<b>8</b>	<b>387</b>	<b>9.1</b>
Nose, Nasal Cavity & Middle Ear	3	1	4	0.1
Larynx	22	1	23	0.5
Lung & Bronchus	353	6	359	8.4
Trachea, Mediastinum & Other Respiratory Organs	1	0	1	0.0
<b>BONES &amp; JOINTS</b>	<b>3</b>	<b>0</b>	<b>3</b>	<b>0.1</b>
<b>SOFT TISSUE (including Heart)</b>	<b>24</b>	<b>4</b>	<b>28</b>	<b>0.7</b>
<b>SKIN EXCLUDING BASAL &amp; SQUAMOUS</b>	<b>296</b>	<b>8</b>	<b>304</b>	<b>7.1</b>
Melanoma—Skin	276	7	283	6.6
Other Non-Epithelial Skin	20	1	21	0.5
<b>BREAST</b>	<b>810</b>	<b>20</b>	<b>830</b>	<b>19.5</b>
<b>FEMALE GENITAL SYSTEM</b>	<b>248</b>	<b>32</b>	<b>280</b>	<b>6.6</b>
Cervix Uteri	17	0	17	0.4
Corpus & Uterus, NOS	158	6	164	3.9
Ovary	49	5	54	1.3
Vagina	1	4	5	0.1
Vulva	8	15	23	0.5
Other Female Genital Organs	15	2	17	0.4
<b>MALE GENITAL SYSTEM</b>	<b>457</b>	<b>34</b>	<b>491</b>	<b>11.5</b>
Prostate	438	34	472	11.1
Testis	18	0	18	0.4
Penis	1	0	1	0.0
<b>URINARY SYSTEM</b>	<b>286</b>	<b>14</b>	<b>300</b>	<b>7.0</b>
Urinary Bladder	164	12	176	4.1
Kidney & Renal Pelvis	105	2	107	2.5
Ureter	4	0	4	0.1
Other Urinary Organs	13	0	13	0.3
<b>EYE &amp; ORBIT</b>	<b>5</b>	<b>1</b>	<b>6</b>	<b>0.1</b>
<b>BRAIN &amp; OTHER NERVOUS SYSTEMS</b>	<b>214</b>	<b>9</b>	<b>223</b>	<b>5.2</b>
Brain	43	3	46	1.1
Cranial Nerves & Other Nervous Systems	171	6	177	4.2
<b>ENDOCRINE SYSTEM</b>	<b>203</b>	<b>17</b>	<b>220</b>	<b>5.2</b>
Thyroid	128	7	135	3.2
Other Endocrine including Thymus	75	10	85	2.0
<b>LYMPHOMA</b>	<b>168</b>	<b>11</b>	<b>179</b>	<b>4.2</b>
Hodgkin's Lymphoma	15	1	16	0.4
Non-Hodgkin's Lymphoma	153	10	163	3.8
<b>MYELOMA</b>	<b>68</b>	<b>7</b>	<b>75</b>	<b>1.8</b>
<b>LEUKEMIA</b>	<b>120</b>	<b>7</b>	<b>127</b>	<b>3.0</b>
Lymphocytic Leukemia	64	3	67	1.6
Acute Lymphocytic Leukemia	3	1	4	0.1
Chronic Lymphocytic Leukemia	60	2	62	1.5
Other Lymphocytic Leukemia	1	0	1	0.0
Myeloid & Monocytic Leukemia	53	4	57	1.3
Acute Myeloid Leukemia	41	1	42	1.0
Chronic Myeloid Leukemia	12	3	15	0.4
Other Leukemia	3	0	3	0.1
Other Acute Leukemia	1	0	1	0.0
Aleukemic, Subleukemic & NOS	2	0	2	0.0
<b>MESOTHELIOMA</b>	<b>3</b>	<b>0</b>	<b>3</b>	<b>0.1</b>
<b>KAPOSI SARCOMA</b>	<b>3</b>	<b>0</b>	<b>3</b>	<b>0.1</b>
<b>OTHER &amp; UNKNOWN SITES</b>	<b>129</b>	<b>3</b>	<b>132</b>	<b>3.1</b>
<b>TOTAL</b>	<b>4,059</b>	<b>199</b>	<b>4,258</b>	<b>100.0</b>



# Academic Leadership Roles and Awards 2018–2019

Kellogg Cancer Center physicians are active in a broad range of regional and national organizations.

## Mihir Bhayani, MD

- Member, NCI Rare Tumors Task Force
- American Board of Otolaryngology Writers Task Force
- AHNS Prevention and Early Detection Committee, Survivorship Committee
- Program Committee International Federation for Head and Neck Oncology and Surgery

### Editorial:

- Manuscript Reviewer: *Oral Oncology*, *Head and Neck*, *JAMA—Otolaryngology Head and Neck Surgery*, *Oncotarget*, *Otolaryngology Head and Neck Surgery*

## Bruce Brockstein, MD

- Member, Head and Neck Committee, Eastern Cooperative Oncology Group, 2000-present
- *Chicago* magazine Top Doctors, 2006, 2008, 2010, 2012, 2014, 2016

### Editorial:

- Manuscript Reviewer: *Head and Neck*, *Annals of Surgical Oncology*
- Grant Reviewer: Cancer Research UK
- *UpToDate* (Online Textbook), Chapter Editor, Head and Neck Cancer, 2000-present

## Nicholas Campbell, MD

### Editorial:

- Reviewer: *Clinical Lung Cancer*, *Case Reports*

## Claus Fimmel, MD, CPE

- Advisory Board, American Liver Foundation, Chicago Chapter, 2008-present

### Editorial:

- The *Open Proteomics Journal* (ISSN 1875-0397) (2008-present)
- *Liver Cancer Review Letters* (2009-present)

## David Grinblatt, MD

- Community Oncology Committee, Alliance for Clinical Trials in Oncology, 2010-present

### Editorial:

Ad Hoc Reviewer: *Annals of Oncology*, 1996-present

## Brian Helfand, MD

- Principal Investigator, Prostate Cancer SPORC project concerning genetics underlying active surveillance failures
- Visiting Professorships in Shanghai China
- Member, Bladder Cancer Consortium and Guideline Committee
- Member, Relative Value Scale Update Committee (RUC)
- 45 peer-reviewed publications this year

## Thomas Hensing, MD

- Respiratory Health Association, Lung Cancer Initiative Advisory Council, 2005-present
- Alliance for Clinical Trials in Oncology, Respiratory Committee Member, 2010-present

## Melissa Hogg, MD

- Co-Chair of the HPB Task Force, SAGES
- Co-Chair of the HPB Disease Site Working Group, SSO
- Associate Editor, "Surgical Techniques" Division, *Journal of Surgical Oncology*
- Chair of the Training and Implementation Committee for the International Evidence-Based Consensus Guidelines of Minimally Invasive Pancreas Resections
- Founding Member of the International Consortium on Minimally Invasive Pancreatic Surgery

## Jason Kaplan, MD

- Member, Southwestern Oncology Group (SWOG), Committees on Lymphoma, Myeloma, and Leukemia, 2015-present

## Karen Kaul, MD, PhD

- American Board of Pathology: Appointed Trustee, 2011-present; ACGME Residency Program Review Committee, 2012-present; Secretary, Executive Committee, 2015-present; Communications Task Force, 2012-present; Chair, Test Development & Advisory Committee for Molecular Genetics, 2012-present; Vice President, Executive Committee, 2017; President, Executive Committee, 2018; ABP/PROD Entrustable Professional Activities Task Force, 2017; Maintenance of Certificate Committee, 2012-present; Credentials Committee, 2012-present; ACGME Milestones 2 Committee, 2018-present
- College of American Pathologists, Member, Executive Advisory Board, *Archives of Pathology & Laboratory Medicine*, 2015-present
- PRODS (Pathology Residency Program Directors), Member PRODS Council, 2009-present; Council of Medical Specialty Societies/OPDA representative, 2009-present; Training Residents in Genomics (TRIG) Joint Committee, 2010-present
- Association of Pathology Chairs, Member, 2012-present; elected Chair, GME Committee, 2015-2018; Executive Council, 2015-present
- Ad Hoc Member, NIH/NCI P01 reviewer, 2001-present
- SBIR Review Panels, various (Panel Chairperson 2010-present), 2008-present

- Peer Reviewer, Prostate Cancer Foundation, 2010-present

- Peer Reviewer, University of Chicago CTSA Pilot Program, 2011-present
- Chair, NorthShore Auxiliary Breast/Ovarian Research Program, 2013-present

### Editorial Activities:

- Editorial Board, *Annual Review of Pathology*, 2011-present
- Associate Editor, *Academic Pathology*, 2014-present
- Executive Advisory Board, *Archives of Pathology & Laboratory Medicine*, 2015-present
- Ad Hoc Reviewer: *Cell Growth and Differentiation*, *Pediatric Pathology*, *Cancer*, *Clinical Microbiology Reviews*, *Tubercle*, *Chest*, *Archives of Pathology & Laboratory Medicine*, *Clinical Chemistry*, *American Journal of Clinical Pathology*, 1990-present

## Janardan Khandekar, MD

### Editorial:

- Reviewer: *JAMA Oncology*, *Journal of National Cancer Institute*
- Associate Editor, *Journal of Surgical Oncology*

## Katherine Kopkash, MD

- Oncoplastic Surgery Committee for the American Society of Breast Surgeons
- Chair of Oncoplastic Breast Surgery for Beginners Curriculum Committee, American Society of Breast Surgeons
- Chicago Surgical Society Young Surgeons Committee

## Seth Krantz, MD

- Invited Question Writer, Self-Education Self-Assessment in Thoracic Surgery (SESATS) XIII (13), American Board of Thoracic Surgery

### Editorial:

- Reviewer: *Chest*, *American Journal of Clinical Oncology*, 2016-present; *Annals of Thoracic Surgery*, 2015-present; *Journal of Thoracic and Cardiovascular Surgery*, 2014-present; *Annals of Surgical Oncology*, 2011-present

## Robert Marsh, MD

- Eastern Cooperative Oncology Group, GI Committee

### Editorial Work:

- *American Journal of Clinical Oncology*, *British Medical Journal*, *Cancer*, *Cancer Management and Research*, *Cell*, *European Journal of Surgical Oncology*, *Journal of Cancer Research and Clinical Oncology*, *Journal of Surgical Oncology*, *Journal of the Pancreas*, *Lancet Oncology*, *Public Library of Science*, *Rogers Medical Intelligence Solutions CME Programs*, *Southern Medical Journal*, *Therapeutic Advances in Gastroenterology*

## Leslie Mendoza Temple

- Guest Editor, Complementary Therapies in Medicine special issue of *Medical Cannabis*, for 2021 publication

## Catherine Pesce, MD

- Young Surgeons Committee of the Chicago Surgical Society

## Richard Prinz, MD

- Editorial Review Board: *Surgery*, *Langenbeck's Archives of Surgery*

## Gustavo Rodriguez, MD

- Member, Cancer Prevention and Control Committee, Gynecologic Oncology Group/NGR, 1997-present
- Advisory Board, Gilda's Club, Chicago, IL, 2004-present

## Carol Rosenberg, MD

- Chair of 2018 Cancer Survivorship Symposium, ASCO-ACP-AAFP Advancing Care and Research—A Primary Care and Oncology Collaboration
- Patient-Centered Outcomes Research Initiative (PCORI) National Comparative Effectiveness Evaluation of Survivorship Programs in the United States. LIFE Site Project Supervisor—LIFE Program Participant Program
- Research Investigator, Women's Health Initiative study, National Institutes of Health (NIH), 1999-present

### Awards:

- Myra Rubenstein Weis LIFE Program Grant Award Recipient: Myra Rubenstein Weis Health Resource Center Foundation, NorthShore University HealthSystem, May 2019

*continued >*

#### **Prem Seth, PhD**

- Editorial Board, Cancer Gene Therapy
- Editorial Board, Molecular Therapy—Oncolytics

#### **Daniel Shevrin, MD**

- Director, Advocacy Core Prostate SPOR, Northwestern University, 2003-present
- Medical Director, NorthShore Chapter of US TOO Prostate Cancer Support Group, 2002-present
- Board Member, Cancer Wellness Center; Northbrook, IL, 2010-present
- Member, National Cancer Institute (NCI) GU Steering Committee, 2014-2017

#### **Mark Sisco, MD, FACS**

- Program Committee, Breast Subsection, American Society of Plastic Surgeons, 2015-present
- In-Service Examination Committee, American Society of Plastic Surgeons, 2016-present

#### **Editorial:**

- Editorial Board Member and Peer Reviewer, *Microsurgery*, 2017
- Peer Reviewer, *Cancer Control*, 2017
- Editorial Board Member and Peer Reviewer, *Journal of Surgical Oncology*, 2014-present
- Peer Reviewer, *Journal of Surgical Research*, 2010-present

#### **Norman Smith, MD**

- Member, American Urological Association Relative Value Scale Update Committee (RUC) (2016-present); Coding and Reimbursement Committee (2016-present); Public Policy Council (2015-present)
- Vice Chair, AMA/Specialty Society Relative Value Scale Update Committee (RUC) Relativity Assessment Workgroup (2019-present)

#### **Mark Talamonti, MD**

- Society of Surgical Oncology, Foundation Board of Directors, 2014-2019; Chairman, Corporate Relations Committee, 2017-2019; Chairman, Local Arrangements Committee, 2017-2018
- Western Surgical Association, Membership Committee, 2012-present; Treasurer, 2012-present, Elected President, 2017-2018
- Americas Hepato-Pancreato-Biliary Association, 2018-2020; Finance Committee, 2019-2021; AHPBA Member at Large—Executive Council

#### **Editorial:**

- Editorial Board: *Annals of Surgical Oncology*, *Journal of Surgical Oncology* (Section Editor, *Hepatobiliary and Pancreas*)
- Invited Reviewer: *American Journal of Surgery*, *Annals of Surgery*, *Archives of Surgery*, *Cancer*, *Journal of the American College of Surgeons*, *Journal of Clinical Oncology*, *Oncology*, *Surgery*, *World Journal of Surgery*

#### **Awards:**

- Outstanding Faculty Teacher Award, Department of Surgery, University of Chicago Pritzker School of Medicine, 2017 and 2018
- Castle Connelly and *Chicago* magazine, Top Doctors in America and Chicago, 1995-2018
- *U.S. News & World Report*, Top 1% of Surgeons in America, 2007-2018

#### **Lauren Wiebe, MD**

- Palliative Care Research Cooperative Group, NorthShore Site Organizational Lead, 2017-present
- Palliative Care Research Cooperative Group, Scientific Review Committee Member, 2016-2019
- Palliative Care Research Cooperative Group, Junior Investigator, 2014-present
- Coleman Supportive Oncology Collaborative, Advanced Disease Team, Member, 2016-2018

- 2019 Special Guest Speaker at the PANCan PurpleStride, June 29, 2019 @ Soldier Field

#### **Editorial:**

- Invited Peer Reviewer, *Journal of Oncology Practice*

#### **Awards:**

- Coleman Foundation Grant, 2019-2020

#### **David J. Winchester, MD**

- Director, Rice Foundation, 1998-present
- American Joint Committee on Cancer (AJCC), 2004-present; Vice-Chairman, 2011-present; Committee, 2008-present; Education and Promotions Committee, 2007-present
- American College of Surgeons, Metropolitan Chicago District #2 Committee on Applicants, 1999-present
- Member, Alliance ACS Clinical Research Program, 2012-present
- Elected Member, American Surgical Association, April 2017

#### **Editorial:**

- Member of Editorial Board, *American Journal of Clinical Oncology*, 2006-present; Associate Editor, 2009-present
- Member of Editorial Advisory Board, *American Family Physician*, 2012-present
- Member of Editorial Board, *Journal of Surgical Oncology*, 2015-present
- Ad Hoc Reviewer: *Annals of Surgical Oncology*, *British Journal of Cancer*, *Cancer*, *Canadian Medical Association Journal*, *Clinical Breast Cancer*, *Cancer Control: Journal of the Moffitt Cancer Center*, *Journal of Clinical Oncology*, *The Lancet Oncology*, *World Journal of Surgical Oncology*

#### **Katharine Yao, MD**

- Member, Patient-Reported Outcomes Working Group, American Society of Breast Surgeons
- Member, Publications Committee, American Society of Breast Surgeons
- Member, Practice Advocacy Committee, American Society of Breast Surgeons
- Alliance for Clinical Trials, Prevention Committee, Women's Cancer Working Group Chair
- Vice Chair, National Accreditation Program for Breast Centers
- American College of Radiology, Supplemental Screening for Breast Density, Appropriateness Criteria Breast Imaging Committee
- President-Elect, Chicago Surgical Society
- Dudley P. Allen Visiting Professor at University Hospitals Cleveland Medical Center, September 25, 2019

#### **Editorial Boards:**

- *Surgical Oncology*, 2017-2018
- *Annals of Surgery*, 2017-2018

#### **Grant Awards:**

- Patient Values in Surgical Decision Making for Breast Cancer Surgery. John Wayne Cancer Foundation Grant. Award Recipient, PI: Yao, K. 5/2018-6/2019
- Implementing and Disseminating Risk Stratified Screening for Breast Cancer at NorthShore. Phase I: Identification of High Risk Women (The IDENTIFY Study), Breast and Ovarian Research Pilot, NorthShore University HealthSystem, PI: Yao, K. 5/2019-6/2020
- Invited speaker: Dutch Breast Cancer Conference, Bossche Mamma Congress, June 18-19, 2019

## Locations

#### **Chicago Lake Shore Medical Office (CH)**

680 North Lake Shore Drive, Suite 924  
Chicago, IL 60611

#### **Evanston Breast Center (EVB)**

2650 Ridge Avenue, Evanston, IL 60201

#### **Evanston Hospital (EH)**

2650 Ridge Avenue, Evanston, IL 60201

#### **Evanston Kellogg Cancer Center (EVK)**

2650 Ridge Avenue, Evanston, IL 60201

#### **Evanston Specialty Suites (EV)**

1000 Central Street, Evanston, IL 60201

#### **Glenbrook Breast Center (GBB)**

2050 Pfingsten Road, Suite 130  
Glenview, IL 60026

#### **Glenbrook Hospital (GBH)**

2100 Pfingsten Road, Glenview, IL 60026

#### **Glenbrook John and Carol Walter Ambulatory Care Center (GB)**

2180 Pfingsten Road, Glenview, IL 60026

#### **Glenbrook Kellogg Cancer Center (GBK)**

2180 Pfingsten Road, Suite 1000  
Glenview, IL 60026

#### **Glenbrook Medical Building (GBM)**

2050 Pfingsten Road, Suite 128  
Glenview, IL 60026

#### **Glenview Park Center (GP)**

2400 Chestnut Avenue, Glenview, IL 60026

#### **Gurnee Ambulatory Care Center (GR)**

7900 Rollins Road, Gurnee, IL 60031

#### **Highland Park Ambulatory Care Center (HPS)**

757 Park Avenue West, Highland Park, IL 60035

#### **Highland Park Breast Center (HPB)**

777 Park Avenue West, Suite B400  
Highland Park, IL 60035

#### **Highland Park Hospital (HPH)**

777 Park Avenue West, Room 1260  
Highland Park, IL 60035

#### **Highland Park Kellogg Cancer Center (HPK)—**

#### **Ellen Marks Ambulatory Care Center**

757 Park Avenue West, Suite 1810  
Highland Park, IL 60035

#### **Highland Park Medical Building (HP)**

767 Park Avenue West, Suite B100  
Highland Park, IL 60035

#### **Lake Bluff Medical Building (LB)**

71 Waukegan Road, Suite 700  
Lake Bluff, IL 60044

#### **Mount Prospect Medical Building (MP)**

1329 Wolf Road, Mount Prospect, IL 60056

#### **Northbrook Medical Building (NMB)**

501 Skokie Boulevard, Northbrook, IL 60062

#### **NorthShore Medical Group (SKM)—Skokie**

9933 Woods Drive, Suite 200, Skokie, IL 60077

#### **Skokie Ambulatory Care Center (SK)**

9650 Gross Point Road, Suite 3000  
Skokie, IL 60076

#### **Vernon Hills Specialty Suites (VH)**

225 North Milwaukee Avenue  
Vernon Hills, IL 60061



# Physician Directory



**Matthew Adess, MD**  
Medical Director, Highland Park  
Kellogg Cancer Center  
Expertise: GI Oncology; Benign  
and Malignant Hematology  
Locations: GBK, GR, HPK



**Marc Alonzo, MD**  
Expertise: Interventional Radiology  
Locations: EH, GB, HP



**Thomas Aquisto, MD**  
Director, Interventional Radiology  
Expertise: Interventional Radiology  
Location: EH



**Julian Bailes, MD**  
Chair, Department of Neurosurgery  
Co-Director, NorthShore  
Neurological Institute  
Expertise: Brain and Spine Tumor  
Surgery  
Locations: EV, HPS



**Mihir Bhayani, MD**  
Division Head, Otolaryngology  
Expertise: Head and Neck Cancers;  
Thyroid and Parathyroid Surgery;  
Robotic Surgery  
Locations: EVK, NBM, VH



**William Bloomer, MD**  
Chair, Department of  
Radiation Oncology  
Expertise: Breast Cancer; Prostate  
Cancer; Lung and Gastrointestinal  
Cancer  
Locations: EH, HP



**Michael Blum, MD**  
Expertise: Urologic Oncology  
Locations: EH, HPS



**Bruce Brockstein, MD**  
Division Head, Hematology/Oncology  
Medical Director, Kellogg Cancer  
Center  
Expertise: Head and Neck Cancers;  
Melanoma; Sarcoma  
Locations: EVK, HPK



**Nicholas Campbell, MD**  
Expertise: Lung Cancer; Esophageal  
Cancer; Head and Neck Cancers  
Locations: EVK, HPK



**Shakeel Chowdhry, MD**  
Expertise: Brain and Spine Tumor  
Surgery; Stereotactic Radiosurgery  
Locations: EV, GB



**Peter Colegrove, MD**  
Expertise: Urologic Oncology  
Locations: EV, GB



**Allison DePersia, MD**  
Expertise: High Risk Breast,  
Hereditary Cancer  
Location: EV



**Hector Ferral, MD**  
Expertise: Interventional Radiology  
Location: EH



**Claus Fimmel, MD**  
Expertise: Liver Diseases;  
Gastrointestinal Diseases;  
GI Endoscopy; Liver Biopsy  
Locations: EV, HPS, SK



**Alla Gimelfarb, MD**  
Expertise: Benign and Malignant  
Hematology  
Location: GBK



**David Grinblatt, MD**  
Expertise: Benign and Malignant  
Hematology  
Locations: EVK, GBK



**Britt Hanson, DO**  
Expertise: Melanoma; Benign and  
Malignant Hematology  
Locations: GR, HPK



**Brian Helfand, MD, PhD**  
Division Head, Urology  
Expertise: Prostate Cancer  
Location: GB



**Thomas Hensing, MD, MS**  
Associate Chief Quality Officer  
Expertise: Lung Cancer; Esophageal  
Cancer  
Locations: EVK, GBK



**Marisa Hill, MD**  
Expertise: GI Oncology  
Locations: EH, HP



**Melissa Hogg, MD, MS**  
Director, Liver and Pancreas Surgery  
Expertise: Gastrointestinal Surgical  
Oncology; Pancreatic Cancer;  
Primary and Metabolic Liver  
Tumors; Neuro-endocrine Tumors;  
Cancers of the Stomach &  
Duodenum; Benign Hepatobiliary;  
Small Bowel Tumors; Sarcoma  
Locations: EVK, GBM



**Peter Hulick, MD, MMSc**  
Division Head, Medical Genetics  
Director, Center for Personalized  
Medicine  
Expertise: Medical Genetics  
Locations: EV, HPK



**Mary Tilley Jenkins Vogel, MD**  
Expertise: Gynecologic Oncology  
Locations: EVK, GBK, HPK



**Lynne Kaminer, MD**  
Section Chief, Hematology  
Expertise: Benign and Malignant  
Hematology  
Locations: EVK, GBK



**Jason Kaplan, MD**  
Expertise: Benign and Malignant  
Hematology  
Locations: EV, HP, LB



**Janardan Khandekar, MD**  
Director, Center for  
Molecular Medicine  
Expertise: Endocrine; Breast  
Cancer  
Location: EVK



**Carolyn Kirschner, MD**  
Expertise: Gynecologic Oncology;  
Cancer Survivorship  
Locations: EVK, GBK



**Katherine Kopkash, MD**  
Expertise: Breast Cancer;  
Oncoplastic Breast Surgery; Breast  
Health; Breast Disease and Surgery  
Locations: EVB, GBB



**Seth Krantz, MD**  
Expertise: Lung Cancer;  
Esophageal Cancer; Minimally  
Invasive Thoracic Surgery  
Locations: EVK, HPK, GBK



**Lawrence Krause, MD**  
Expertise: Breast Cancer; Breast  
Health; Breast Disease and Surgery  
Locations: GR, HPB, SK

# Physician Directory

continued >



**Monika Krezalek, MD**  
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease; Anorectal Surgery; Colonoscopy  
Locations: EV, HPS, GR



**Teresa Murray Law, MD**  
Expertise: Breast Cancer; Prostate Cancer; Genitourinary Cancer  
Locations: EVK, GR, HPK



**Ross Levy, MD**  
Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery  
Location: SKM



**John Linn, MD**  
*Vice Chair for Surgery, Glenbrook Hospital*  
Expertise: Gastrointestinal Surgical Oncology Including Stomach and Esophagus; Weight Loss Surgery; General Surgery  
Locations: EV, GBM



**Luzheng Liu, MD**  
Expertise: General Dermatology; Skin Cancers  
Location: LB



**Konanahalli Madhuri, MD**  
Expertise: Skin Cancer; General Dermatology  
Location: EV



**Robert Marsh, MD**  
*Section Chief, GI Oncology*  
Expertise: GI Oncology  
Locations: EVK, GBK




**Andrew Melnyk, MD**  
Expertise: Medical Genetics  
Locations: EV, GBM



**Gregg Menaker, MD**  
Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery  
Location: SKM




**Douglas Merkel, MD**  
Expertise: Breast Cancer  
Locations: EVK, GBK, HPK



**Ryan Merrell, MD**  
*Program Director, Neuro-Oncology*  
Expertise: Brain Cancer; Brain Tumor; Neurologic Complications of Cancer; Tumor in the Central Nervous System (Brain or Spine)  
Locations: EVK, GB, GBK




**Tricia Moo-Young, MD**  
Expertise: Minimally Invasive Approaches to Endocrine Disorders; Thyroid and Parathyroid Surgery; Adrenal Disorders; Pancreatic Exocrine; General Surgery  
Locations: HPS, VH



**Elena Moore, MD**  
Expertise: Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer  
Locations: EVK, HPK



**Joseph Muldoon, MD**  
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease; General Surgery  
Locations: EV, GBK, GBM



**Ranjeev Nanda, MD**  
Expertise: Stereotactic Radiosurgery; Brain Tumors; Head and Neck Cancers  
Locations: EH, GBH



**Cheryl Nocon, MD**  
Expertise: Head and Neck Cancers; Thyroid and Parathyroid Surgery; Microvascular Reconstruction  
Locations: EVK, SK, VH



**Kristian Novakovic, MD**  
Expertise: Kidney Cancer; Prostate Cancer  
Locations: EV, GB



**Bernhard Ortel, MD**  
*Division Head, Dermatology*  
Expertise: Skin Cancer; General Dermatology; Psoriasis; Blistering Diseases  
Location: SKM



**Sangtae Park, MD, MPH**  
Expertise: Prostate Cancer; Urologic Oncology  
Locations: EV, GB



**Catherine Pesce, MD**  
*Director, Surgical Breast Program*  
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery  
Locations: HPB, HPK



**Nicklas Pfanzer, MD**  
Expertise: Genitourinary Cancer; Lung Cancer  
Locations: EV, GB, HP



**Ariel Polish, MD**  
Expertise: GI Oncology; Benign and Malignant Hematology; Genitourinary Cancer; Lung Cancer  
Locations: EVK, GBK, GR



**Richard Prinz, MD**  
*Vice Chair, Administration & Clinical Development, Department of Surgery*  
Expertise: Endocrine Surgery with Emphasis on Thyroid, Parathyroid, Adrenal and Pancreatic Neuroendocrine Surgery  
Locations: EV, HPS, MP




**Amit Pursnani, MD**  
Expertise: Cardiac Oncology; Clinical Cardiology  
Locations: EV, SK



**Vathsala Raghavan, MD**  
Expertise: Breast Cancer; Gynecologic Oncology; Head and Neck Cancers; Thyroid Cancer  
Locations: GBH, HPH



**Joseph Raviv, MD**  
Expertise: Endoscopic Sinus and Anterior Skull Base Surgery  
Locations: EV, NMB



**Erwin Robin, MD**  
Expertise: Benign and Malignant Hematology  
Locations: GB, HP, SK



**Gustavo Rodriguez, MD**  
*Division Head, Gynecologic Oncology*  
Expertise: Gynecologic Oncology  
Location: EVK



# Cancer Conferences



**Carol Rosenberg, MD**  
*Director, Preventive Health Initiatives;  
 Director, Myra Rubenstein Weis  
 Living in the Future (LIFE) Cancer  
 Survivorship Program*  
 Expertise: Cancer Survivorship  
 Location: HPH



**Poornima Saha, MD**  
 Expertise: Breast Cancer  
 Locations: EVK, HPK, LB



**Akhil Seth, MD**  
 Expertise: Breast Reconstruction;  
 Aesthetic Breast and Body Surgery;  
 Oncologic and Complex Wound  
 Reconstruction  
 Location: NMB



**Arif Shaikh, MD**  
 Expertise: Stereotactic Radiosurgery;  
 Head and Neck Cancers; Lung  
 Cancer; Gynecologic and Breast  
 Tumors  
 Locations: EH, GBH



**Daniel Shevrin, MD**  
*Medical Director, Glenbrook  
 Kellogg Cancer Center*  
 Expertise: Prostate Cancer;  
 Genitourinary Cancer  
 Locations: EVK, GBK



**Michael Shinnars, MD**  
 Expertise: Otolaryngology/Neurotology;  
 Lateral Skull Base Surgery  
 Locations: EV, NMB



**Mark Sisco, MD**  
*Division Head, Plastic and  
 Reconstructive Surgery*  
 Expertise: Plastic Surgery;  
 Breast Reconstruction  
 Location: NMB



**Norm Smith, MD**  
 Expertise: Bladder Cancer,  
 Testicular Cancer, Kidney Cancer,  
 Advanced Urologic Cancers,  
 Locations: EV, GB



**James Spitz, MD**  
 Expertise: Colon and Rectal Surgery;  
 Colonoscopy; General Surgery  
 Locations: GBM, SK, VH



**Mark Talamonti, MD**  
*Department Chair, Surgery*  
 Expertise: Gastrointestinal Surgical  
 Oncology; Pancreatic Cancer;  
 Benign and Malignant Liver Tumors;  
 Neuroendocrine Tumors  
 Location: EVK



**Leslie Mendoza Temple, MD**  
*Integrative Medicine Medical Director*  
 Expertise: Integrative Medicine  
 Location: GP



**Michael Ujiki, MD**  
*Division Head, Gastrointestinal  
 & General Surgery*  
 Expertise: Gastrointestinal Surgical  
 Oncology including Stomach and  
 Esophagus; Minimally Invasive  
 Endoscopic Surgery; Weight Loss  
 Surgery; General Surgery  
 Locations: EV, GBM



**Elaine Lee Wade, MD**  
 Expertise: Breast Cancer;  
 Benign Hematology  
 Location: GBK



**Jason Waldinger, MD**  
 Expertise: Skin Cancer; General  
 Dermatology; Laser Procedures  
 Location: LB



**Lauren Wiebe, MD**  
 Expertise: Palliative Medicine;  
 GI Oncology  
 Locations: EH, GB



**David J. Winchester, MD**  
*Associate Director for Surgical  
 Specialties, Kellogg Cancer Center*  
 Expertise: Surgical Oncology with  
 Emphasis on Breast, Endocrine,  
 Melanoma and Sarcoma  
 Locations: EV, EVB, GBB, GBM



**Ricky Wong, MD**  
 Expertise: Brain, Skull and  
 Pituitary Tumors  
 Locations: EV, GB



**Katharine Yao, MD**  
*Division Head, Surgical Oncology*  
 Expertise: Breast Cancer; Breast  
 Health; Breast Disease and Surgery  
 Locations: EVB, EVK

## Breast Cancer Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868, Mondays, 7:30 a.m.  
 NorthShore Glenbrook and Highland Park  
 Hospitals Videocast

## Colorectal Cancer Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868  
 2nd and 4th Fridays, 7 a.m.  
 NorthShore Glenbrook and Highland Park  
 Hospitals Videocast

## Genitourinary Cancer Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868  
 1st and 3rd Fridays, 7 a.m.  
 NorthShore Glenbrook Hospital Videocast

## Gynecology Cancer Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868, Thursdays, 7 a.m.  
 NorthShore Glenbrook and Highland Park  
 Hospitals Videocast

## Head and Neck Cancer Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868  
 1st and 3rd Thursdays, 8 a.m.

## Hematology/Pathology Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868  
 Tuesdays, 8:00 a.m.  
 NorthShore Glenbrook and Highland Park  
 Hospitals Videocast

## Hepatic Biliary Pancreatic Cancer Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868, Tuesdays, 7 a.m.  
 NorthShore Glenbrook and Highland Park  
 Hospitals Videocast

## Molecular Oncology Conferences

NorthShore Evanston Hospital  
 Kellogg Room 4818, 1st Friday, 7 a.m.

## Neuro-Oncology Cancer Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868  
 2nd and 4th Wednesdays, 7:30 a.m.  
 NorthShore Glenbrook and Highland Park  
 Hospitals Videocast

## Sarcoma/Melanoma Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868  
 1st and 3rd Wednesdays, 8 a.m.  
 NorthShore Glenbrook and Highland Park  
 Hospitals Videocast

## Thoracic Cancer Conferences

NorthShore Evanston Hospital  
 Kellogg Room G868, Tuesdays, noon  
 NorthShore Glenbrook and Highland Park  
 Hospitals Videocast

**Evanston Hospital**  
2650 Ridge Avenue  
Evanston, Illinois 60201  
(847) 570-2000

**Glenbrook Hospital**  
2100 Pfingsten Road  
Glenview, Illinois 60026  
(847) 657-5800

**Highland Park Hospital**  
777 Park Avenue West  
Highland Park, Illinois 60035  
(847) 432-8000

**Skokie Hospital**  
9600 Gross Point Road  
Skokie, Illinois 60076  
(847) 677-9600

**Medical Group**  
1301 Central Street  
Evanston, Illinois 60201  
(847) 570-5235

**Foundation**  
1033 University Place, Suite 450  
Evanston, Illinois 60201  
(224) 364-7200

**Research Institute**  
1001 University Place  
Evanston, Illinois 60201  
(224) 364-7100

A publication of the Office of Corporate Communications

EDITOR: Amy Ferguson, Assistant Vice President, Integrated Marketing and Corporate Communications

PHOTOGRAPHY: Allen Bourgeois, Jon Hillenbrand

WRITER: Susan J. White



1301 Central Street  
Evanston, Illinois 60201

[northshore.org](http://northshore.org)

## Cancer Committee 2019

### Chairman

**David J. Winchester, MD, FACS**  
Associate Director for Surgical Specialties,  
Kellogg Cancer Center,  
NorthShore Cancer Committee Chairman,  
Board of Directors, David P. Winchester, MD,  
Chair of Surgical Oncology

### Physician Membership\*

**Matthew Adess, MD**  
Medical Director, Highland Park  
Kellogg Cancer Center

**Kristina Drabkin, DO**  
Physical Medicine & Rehabilitation

**David Grinblatt, MD**  
Director, Oncology Research Program  
Kellogg Cancer Center

**Thomas Hensing, MD**  
Co-Director, Thoracic Oncology Program  
Head of Quality, Kellogg Cancer Center  
Deputy Division Head,  
Division of Hematology and Oncology  
Medical Director, Evanston Kellogg Cancer  
Center  
NorthShore Cancer Committee Quality  
Improvement Coordinator

**Seth Krantz, MD**  
Thoracic Oncology  
NorthShore Cancer Committee Cancer  
Liaison Physician

**Elena Moore, MD**  
Gynecologic Oncology

### Vice Chairman

**Bruce Brockstein, MD**  
Medical Director, Kellogg Cancer Center,  
Head, Division of Hematology/Oncology,  
Kellogg-Scanlon Chair of Oncology,  
NorthShore Cancer Committee Vice-Chairman,  
NorthShore Cancer Committee Cancer  
Conference Coordinator

**Kristian Novakovic, MD**  
Urologic Oncology

**Catherine Pesce, MD**  
Surgical Oncology

**Vathsala Raghavan, MD**  
Radiation Oncology

**Carol Rosenberg, MD**  
Director, Myra Rubenstein Weis  
Living in the Future (LIFE) Cancer  
Survivorship Program

**Poornima Saha, MD**  
Medical Oncology

**Arif Shaikh, MD**  
Radiation Oncology

**Lauren Wiebe, MD**  
Palliative Care

### Ancillary Membership

**Jonella Black, PT, MS**  
Program Coordinator, Rehab Services

**George Carro, RPH, MS, BCOP**  
Senior Director, Oncology Pharmacy

**Kim Cholewa, BSN**  
Oncology Nursing

**Jamie Feld, RN**  
Cancer Committee Coordinator  
Cancer Registry

**Amy Ferguson**  
Assistant Vice President,  
Integrated Marketing and  
Corporate Communications

**Laurel Gage, RHIT, CTR**  
Cancer Registry Abstractor II  
Kellogg Cancer Center

**Addie Gorchow, MBA, RHIT, CTR**  
Senior Manager, Cancer Registry

**Linda Green, RN, MS, AOCNS**  
Director, Medical Group Operations,  
Oncology Nursing, Kellogg Cancer Center

**Rachel Mees**  
Assistant Vice President,  
Medical Group  
Kellogg Cancer Center

**Sabina Omercajic, MS, CCRP**  
Outreach Coordinator  
Kellogg Cancer Center  
NorthShore Cancer Committee  
Community Outreach Coordinator

**Anisha Patel, APN**  
Clinical Coordinator  
Living in the Future (LIFE)  
Cancer Survivorship Program

**Shayna Purcell, MSCGC**  
Medical Genetics

**Denise Rehberger, RN, BSN**  
Manager, Hospice

**Kelly Tinnes**  
Health Systems Manager  
American Cancer Society

**Roslyn Turner, LSW**  
Oncology Social Worker  
Kellogg Cancer Center  
NorthShore Cancer Committee  
Psychosocial Services Coordinator

**Maria Velez**  
Coordinator, IRB Research  
Oncology Research  
NorthShore Cancer Committee  
Clinical Research Coordinator

**Debra Ziegler, MLIS, CTR**  
Quality Coordinator, Cancer Registry  
NorthShore Cancer Committee  
Cancer Registry Quality Coordinator

**Lisa Zoberman, RDN, LDN**  
Oncology Nutrition  
Kellogg Cancer Center



\* All academic affiliations are with the University of Chicago Pritzker School of Medicine